Epidermolysis bullosa acquisita: the most frequent pemphigoid disease in patients with dermal binding autoantibodies by indirect immunofluorescence microscopy on human salt‐split skin in Tehran, Iran

Daneshpazhooh, Maryam; Fazlolahi, Samaneh; Mahmoudi, Hamidreza; Atefi, Ingeborg; Beek, Nina van; Balighi, Kamran; Fazli, Jafar Taghizadeh; Kamyab, Kambiz; Zillikens, Detlef; Schmidt, Enno

doi:10.1111/jdv.17137

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article1

Other1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ELISA (non-collagenous 1 domain) for detection of anti-COL7 antibodies. 5 Original or biosimilar RTX was administered based on two protocols: RTX 500 mg weekly for four weeks or RTX 1,000 mg for two biweekly infusions. 6 Due to the lack of a consensus statement on definitions of disease endpoints for EBA, we employed definition outcome measures for mucous membrane pemphigoid.…”

mentioning

confidence: 99%

Rituximab for the treatment of epidermolysis bullosa acquisita: A large case series of 15 patients

Dasdar

Kianfar

Tavakolpour

et al. 2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

mentioning

confidence: 99%

Rituximab for the treatment of epidermolysis bullosa acquisita: A large case series of 15 patients

Dasdar

Kianfar

Tavakolpour

et al. 2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Immunobullous Diseases

Schmidt,

Groves

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

The immunobullous disorders represent a group of conditions characterised by antibody‐mediated autoimmune responses against structural elements of the skin resulting in blistering of the skin and/or mucosae. Antibody targets include proteins in the hemidesmosomes basement membrane zone and superficial dermis (pemphigoid group), desmosomes (pemphigus group) and epidermal and tissue‐type transglutaminase (dermatitis herpetiformis). If left untreated, immunobullous disorders are associated with significant morbidity and mortality and thus prompt, accurate diagnosis and treatment are mandatory. Therapeutic options include corticosteroids, steroid‐sparing immunosuppressants such as azathioprine, mycophenolate mofetil and anti‐inflammatory agents such as dapsone and tetracyclines. In severe and/or refractory patients, intravenous immunoglobulin, immunoadsorption and anti‐B‐cell agents such as rituximab may be of benefit. Indeed, recently international and European guidelines have recommended the use of rituximab as first line treatment in moderate and severe pemphigus vulgaris and foliaceous.

show abstract

Epidermolysis bullosa acquisita: the most frequent pemphigoid disease in patients with dermal binding autoantibodies by indirect immunofluorescence microscopy on human salt‐split skin in Tehran, Iran

Abstract: ubeck, L€ ubeck, for help with the serum analyses. The patients in this manuscript have given written informed consent to publication of their case details.

Cited by 2 publications

References 10 publications

Rituximab for the treatment of epidermolysis bullosa acquisita: A large case series of 15 patients

Rituximab for the treatment of epidermolysis bullosa acquisita: A large case series of 15 patients

Immunobullous Diseases

Contact Info

Product

Resources

About